NDAORALTABLET
Approved
May 2021
Lifecycle
Peak
Competitive Pressure
0/100
Data completeness
4/8 — Partial
MYFEMBREE (relugolix, estradiol hemihydrate, and norethindrone acetate) by Sumitomo Dainippon Pharma is gonadotropin releasing hormone receptor antagonists [moa]. First approved in 2021.
Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
MYFEMBREE is an oral tablet combining relugolix (a GnRH receptor antagonist) with estradiol and norethindrone acetate (hormonal add-back). It is indicated for moderate to severe endometriosis pain in women. The mechanism suppresses ovarian hormone production via GnRH antagonism while add-back hormones mitigate hypoestrogenic side effects.
$0.002BPart D
Peak16.5 years to LOEEarly-stage peak sales with modest claims volume (1,153 in 2023) suggest commercial team is in market development phase with room for expansion in the endometriosis segment.
Mechanism of Action
Gonadotropin Releasing Hormone Receptor Antagonists
Pharmacologic Class:
Gonadotropin Releasing Hormone Receptor Antagonist
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
MYFEMBREE currently shows zero linked career postings, suggesting limited external hiring or that recruitment is managed through internal Sumitomo Dainippon channels. This niche women's health product likely recruits specialized medical affairs, regulatory, and field-based commercial talent.
Company
Worked on MYFEMBREE at Sumitomo Dainippon Pharma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.